Nothing Special   »   [go: up one dir, main page]

WO2008025870A1 - Compositions utiles en particulier dans le traitement ou la prévention du syndrome métabolique - Google Patents

Compositions utiles en particulier dans le traitement ou la prévention du syndrome métabolique Download PDF

Info

Publication number
WO2008025870A1
WO2008025870A1 PCT/FI2007/000206 FI2007000206W WO2008025870A1 WO 2008025870 A1 WO2008025870 A1 WO 2008025870A1 FI 2007000206 W FI2007000206 W FI 2007000206W WO 2008025870 A1 WO2008025870 A1 WO 2008025870A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
food
metabolic syndrome
oxidase enzyme
amine oxidase
Prior art date
Application number
PCT/FI2007/000206
Other languages
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Priority to EP07803696A priority Critical patent/EP2056830A4/fr
Publication of WO2008025870A1 publication Critical patent/WO2008025870A1/fr
Priority to US12/060,533 priority patent/US8119651B2/en
Priority to US13/354,025 priority patent/US20120115815A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to the use of vitamin Bl, vitamin Bl derivatives or vitamin Bl precursors as inhibitors of semicarbazide-sensitive amine oxidases (SSAO), in particular for use in treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom. Furthermore, the invention concerns food products and food additives comprising said amine oxidase enzyme inhibitor as well as the use of said inhibitor as an additive to a foodstuff or as a dietary supplement.
  • SSAO semicarbazide-sensitive amine oxidases
  • VAP-I is a human endothelial cell adhesion molecule that has several unique properties that distinguish it from the other inflammation-related adhesion molecules.
  • One of the most interesting features of VAP-I is a catalytic extracellular domain which contains a monoamine oxidase activity (Smith, D. J., et al., J. Exp. Med 188:17-27 (1998)).
  • VAP-I is an ecto-enzyme.
  • VAP- 1 belongs to the class of membrane-bound MAO's termed semicarbazide-sensitive amine oxidases (SSAO). These are distinguished from the widely distributed mitochondrial MAO-A and B flavoproteins by amino acid sequence, cofactor, substrate specificity and sensitivity to certain inhibitors. However, certain substrates and inhibitors are common to both SSAO and MAO activities.
  • the mammalian SSAO's can metabolize various monoamines produced endogenously or absorbed as dietary or xenobiotic substances. They act principally on primary aliphatic or aromatic monoamines such as methylamine or benzylamine (Lyles G. A., Int. J. Biochem. Cell Biol, 28:259-274 (1996)).
  • VAP-I located on the vascular endothelial cell surface can act on circulating primary monoamines with the following reaction pathway.
  • methylamine is a good substrate for VAP-I SSAO.
  • Methylamine is a product of various human biochemical pathways for the degradation of creatinine, sarcosine and adrenaline, and is found in various mammalian tissues and in blood. It can also be derived from the diet by gut bacterial degradation of dietary precursors. The concentration of methylamine in the blood can be increased in certain physiological and pathological situations such as diabetes.
  • Another potential physiological substrate is aminoacetone.
  • VAP-I SSAO activity has been proposed to be directly involved in the pathway of leukocyte adhesion to endothelial cells by a novel mechanism involving direct interaction with an amine substrate presented on a VAP-I ligand expressed on the surface of a leukocyte (Salmi et al. Immunity, vol. 14, pp. 265-276 (2001)).
  • This publication describes the direct involvement of VAP-I SSAO activity in the process of adhesion of leukocytes to endothelium.
  • inhibitors of VAP-I SSAO activity could be expected to reduce leukocyte adhesion in areas of inflammation and thereby reduce leukocyte trafficking into the inflamed region and therefore the inflammatory process itself.
  • VAP-I is induced at sites of inflammation.
  • This increased level of VAP-I can lead to increased production of H 2 O 2 generated from the action of the VAP-I SSAO extracellular domain on monoamines present in the blood.
  • This generation OfH 2 O 2 in the localized environment of the endothelial cell could initiate other cellular events.
  • H 2 O 2 is a known signaling molecule that can upregulate other adhesion molecules and this increased adhesion molecule expression may lead to enhanced leukocyte trafficking into areas in which VAP-I is expressed.
  • other products of the VAP-I SSAO reaction could have biological effects also contributing to the inflammatory process.
  • the products of the VAP-I SSAO activity may be involved in an escalation of the inflammatory process which could be blocked by specific SSAO inhibitors.
  • VAP-I SSAO may be involved in a number of other pathological conditions associated with an increased level of circulating amine substrates of VAP-I SSAO.
  • the oxidative deamination of these substrates would lead to an increase in the level of toxic aldehydes and oxygen radicals in the local environment of the endothelial cell which could damage the cells leading to vascular damage.
  • the vasculopathies such as retinopathy, neuropathy and nephropathy could be treated with specific inhibitors of SSAO activity.
  • N-alkylaminoephedrines including N- (isopropylideneamino)-ephedrine or R,S-(+)-(2 -hydroxy- l-methyl-2- phenylethyl)methylhydrazone-2-propanone.
  • These hydrazone compounds were synthesized to evaluate their effect on the bronchial musculature and were found not to exhibit any significant activity.
  • Grifantini M., et al., Farmaco, Ed.Sci.23(3): 197-203 (1968), report the synthesis of several alkyl- and acyl-derivatives of N-amino-1-ephedrine and N-amino-d- pseudoephedrine having antidepressant and monoamine oxidase inhibitory properties.
  • Jeffrey O'Sullivan et al., Biochimica et Biophysica Acta 1647 (2003) 367-371 report the inhibition of semicarbazide-sensitive amine oxidases by certain aminohexoses, namely glucosamine, galactosamine and mannosamine.
  • the international patent publications WO 02/020290 and WO 03/006003 disclose certain hydrazino compounds useful as specific VAP-I SSAO inhibitors that modulate VAP-I activity. These compounds are described as useful for the treatment of acute and chronic inflammatory conditions or diseases as well as diseases related to carbohydrate metabolism, aberrations in adipocyte differentiation or function and smooth muscle cell function, and various vascular diseases.
  • VAP- 1 vascular adhesion protein- 1
  • an end product of the SSAO metabolism hydrogen peroxide
  • amine oxidase enzyme activity is increased in metabolic syndrome as an attempt to regulate blood glucose levels, and that complications resulting from metabolic syndrome are subsequently promoted as a consequence of the enhanced enzyme activity.
  • the invention concerns the use of vitamin Bl, a vitamin Bl derivative or a vitamin B 1 precursor for the manufacture of a pharmaceutical preparation useful as an amine oxidase enzyme inhibitor in a non-diabetic individual, especially for use in the treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom.
  • the invention concerns a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, wherein said amine oxidase enzyme inhibitor is a vitamin Bl derivative or a vitamin Bl precursor.
  • the invention concerns a food additive comprising an amine oxidase enzyme inhibitor, which is a vitamin B 1 derivative or a vitamin B 1 precursor, in combination with a liquid, solid or semisolid carrier.
  • an amine oxidase enzyme inhibitor which is a vitamin B 1 derivative or a vitamin B 1 precursor
  • the invention concerns vitamin Bl, a vitamin Bl derivative or a vitamin Bl precursor for use as an amine oxidase enzyme inhibitor in a non-diabetic individual, especially for use in the treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom.
  • the invention concerns a method for treatment or prevention of diseases or conditions in a non-diabetic individual, benefiting from inhibition of an amine oxidase enzyme, particularly for treating or preventing metabolic syndrome and diseases or conditions resulting therefrom in a non-diabetic individual, said method comprising administering to the individual an effective amount of vitamin Bl, a vitamin Bl derivative or a vitamin Bl precursor.
  • the invention concerns novel vitamin Bl derivatives in which the pyrimidine ring of thiamine is replaced by another aromatic group.
  • the invention concerns vitamin Bl derivatives in which the pyrimidine ring of thiamine is replaced by another aromatic group, for use in therapy.
  • the invention concerns vitamin Bl derivatives in which the pyrimidine ring of thiamine is replaced by another aromatic group, for use as amine oxidase enzyme inhibitors, especially for use in the treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom.
  • metabolic syndrome shall be understood to include the following abnormalities: central obesity, dyslipidemia including particularly hypertriglyceridemia, low HDL cholesterol, small dense LDL particles and postpranial lipemia; glucose intolerance such as impaired fasting glucose; insulin resistance and hypertension.
  • Metabolic syndrome is not the same as diabetics. Metabolic syndrome is considered as accumulation of conditions potentially leading to coronary diseases. Such conditions are middle body obesity, hypertriglyceridemia, low high density cholesterol, high blood pressure and increased fasting blood glucose. The individuals affected by metabolic syndrome do not need to have diabetes.
  • disorders related to metabolic syndrome shall be understood to include any disease or disorder resulting from said syndrome.
  • diseases are particularly different types of microalbuminuria; impaired fibrinolysis and increased coagulability including elevated PAI-I, elevated fibrinogen and increased levels of von Willebrand factor; signs of chronic inflammation such as elevated CRP; endothelial dysfunction such as impaired endothelium-dependent vasodilation; fatty liver disease and microangiopathy.
  • Atherosclerosis vascular retinopathies, retinopathy, glomerulosclerosis, nephropathy, nephrotic syndrome, polyneuropathy, mononeuropathies, autonomic neuropathy, glaucoma, grey cataract, foot ulcers, joint problems, and increased risk of infection.
  • a person is suffering from metabolic syndrome in case the following criteria are fulfilled: Central obesity; waist circumference > 94 cm (male) and > 80 cm (female) and
  • prevention shall be understood to include complete prevention, prophylaxis, as well as lowering the individual's risk of falling ill with said disease or condition.
  • the term shall also be understood to include alleviation of symptoms already developed.
  • treatment shall be understood to include complete curing of a disease or condition, as well as amelioration or alleviation of said disease or condition.
  • the term "individual” refers to a human or animal subject.
  • amine oxidase enzyme inhibitor shall here be understood to cover any vitamin Bl derivative or vitamin Bl precursor (prodrug) known or still undiscovered compound having this activity. It shall also be understood to cover any isomer, isomeric mixture, and any pharmaceutically or physiologically acceptable salt of such a compound.
  • the amine oxidase enzyme inhibitor is especially useful in the treatment or prevention of complications derived from metabolic syndromes.
  • the amine oxidase enzyme inhibitor, its isomer, isomer mixture or its pharmaceutically acceptable salt can be administered by various routes.
  • administration can be by parenteral, subcutaneous, intravenous, intraarticular, intrathecal, intramuscular, intraperitoneal, or intradermal injections, or by transdermal, buccal, oromucosal, ocular routes or via inhalation.
  • administration can be by the oral route.
  • Particularly preferred is oral administration.
  • Suitable oral formulations include e.g. conventional or slow-release tablets and gelatine capsules.
  • the required dosage of the compounds will vary with the particular disease or condition being treated, the severity of the condition, the duration of the treatment, the administration route and the specific compound being employed.
  • a typical dose is in the dosage range of about 0.1 microgram/kg to about 300 mg/kg, preferably between 1.0 microgram/kg to 10 mg/kg body weight.
  • Compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
  • the term "foodstuff” shall be understood as any edible ingredient of plant or animal origin or synthetically prepared, which is useful as an energy supplier to the mammalian body. It can thus include carbohydrates, proteins or fats or their mixtures and/or compositions with other ingredients, especially with water.
  • the foodstuff can be a basic foodstuff such as vegetables, cereals, flour, milk, meat, egg, butter, margarine, etc.
  • foodstuff shall also be considered any finished compositions, such as bread, cakes, yogurt and other milk products, finished meals etc.
  • the food product according to this invention is any food product, but especially a functional food, a nutritional supplement, a nutrient, a pharmafood, a nutraceutical, a health food, or a designer food.
  • a suitable concentration of the amine oxidase enzyme inhibitor depends on the particular inhibitor used as well on the food product in question.
  • the functional food according to this invention can be any foodstuff supplemented with an amine oxidase enzyme inhibitor.
  • the amine oxidase enzyme inhibitor in principle could be added as such to a food manufacturing process, it may be preferable in order to achieve exact dosing to first mix the inhibitor with a carrier before it is added to the food manufacturing process.
  • This invention concerns also a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.
  • the carrier can be any edible, non-toxic solid, semi-solid or liquid carrier acceptable for use in food and suitable to be admixed with the amine oxidase enzyme inhibitor without affecting the properties of the inhibitor.
  • the role of the carrier is mainly to make the exact dosage of amine oxidase enzyme inhibitor easier.
  • the suitable concentration of the inhibitor in the food additive depends on the inhibitor in question and the proposed use of the food additive.
  • the food additive according to this invention can according to one alternative be used by food industry in processing various food products comprising a foodstuff supplemented with an amine oxidase enzyme inhibitor.
  • the food additive it is conveniently packed in a package suitable for industrial use in the addition of the additive in the food manufacturing process.
  • the food additive can be directly used by the consumer, e.g. by dosing a certain amount of food additive onto a meal to be in- taken.
  • the food additive is in the form of a unit dosage to be used as a dietary supplement.
  • the wording "food additive" shall not be interpreted narrowly to mean that the food additive always first must be added to a foodstuff before the intake by the consumer.
  • a dietary supplement can be in-taken directly without first mixing it with a foodstuff.
  • the dietary supplement can be in-taken in connection with a meal, but it could alternatively be in-taken between two meals.
  • vitamin Bl derivative shall here be understood to cover any vitamin Bl derivative, especially compounds having SSAO inhibiting activity. Especially preferred are those having no angiotensive converting enzyme-inhibiting action or quininase inhibiting action. Particularly preferred vitamin Bl derivatives are compounds in which the pyrimidine ring of thiamine is replaced by another aromatic group, for example but not restricted to, a phenyl group, which may be substituted or unsubstituted. As a particularly preferred compound can be mentioned 3-(2-aminobenzyl)-5-(2-hydroxyethyl)-4-methyl-thiazolium chloride hydrochloride, which has the structure formula
  • a particularly preferable precursor (or prodrug) for vitamin Bl is the compound benfotiamine, which is fat soluble.
  • Typical dosage forms for a dietary supplement comprising an amine oxidase enzyme inhibitor include, but are not limited to, oral dosage forms such as powders, granules, capsules, tablets, caplets, lozenges, liquids, elixirs, emulsions and suspensions. All such dosage forms may include conventional carriers, diluents, excipients, binders and additives known to those skilled in the art.
  • Typical solid carriers include polysaccarides such as lactose, sucrose, gelatin, agar, while liquid carriers include aqueous solutions of salts, polysaccarides, complexing agents, surfactants, syrups, vegetable oils such as peanut oil or olive oil, and certain alcohols.
  • any acceptable solid, semisolid or liquid carrier can be used in the food additive according to the invention.
  • a food additive formulation being a mixture of only the active agent and plain water is expected to be less feasible.
  • the food product and food additive described above are particularly useful for person suffering from or at risk of metabolic syndrome, these products may have valuable health promoting effects also in other individuals, particularly in individuals suffering from or being at risk of diseases or conditions caused by increased amine oxidase enzyme activity.
  • diseases or conditions can be mentioned inflammatory diseases or conditions; diseases related to aberrations in adipocyte differentiation or function or smooth muscle cell function and vascular diseases.
  • inflammatory diseases or conditions can be mentioned - connective tissue inflammatory diseases or conditions such as ankylosing spondylitis, Reiter's syndrome, psoriatic arthritis, osteoarthritis or degenerative joint disease, rheumatoid arthritis, Sjogren's syndrome, Bechet's syndrome, relapsing polychondritis, systemic lupus erythematosus, discoid lupus erythematosus, systemic sclerosis, eosinophilic fasciitis, polymyositis and dermatomyositis, polymyalgia rheumatica, vasculitis, temporal arteritis, polyarterisis nodosa, Wegner's granulomatosis, mixed connective tissue disease, and juvenile rheumatoid arthritis, - gastrointestinal inflammatory diseases or conditions, such as Crohn's disease, ulcerative colitis, irritable bowel syndrome (spastic colon
  • pulmonary inflammatory diseases or conditions such as asthma, chronic obstructive pulmonary disease, or adult respiratory distress syndrome
  • Atherosclerosis As examples of diseases relating to aberrations in adipocyte differentiation or function or smooth muscle cell function can be mentioned atherosclerosis and obesity.
  • vascular diseases can be mentioned atheromatous arteriosclerosis, nonatheromateous arteriosclerosis, ischemic heart disease, peripheral arterial occlusion, thromboangiitis obliterans (Buerger's disease), or Raynaud's disease and phenomenon.
  • mice Despite a decreased caloric intake the transgenic mice had increased weight, body mass index (BMI), and subcutaneous abdominal and epididymal white adipose tissue (WAT) deposits when compared to controls.
  • BMI body mass index
  • WAT subcutaneous abdominal and epididymal white adipose tissue
  • VAP-I overexpression increases advanced glycation end product (AGE) formation.
  • AGE-peptide levels were measured by fluorescence spectroscopy in the sera of the 64 week old mice.
  • the level of AGE-specific fluorescence (ex 360, em 465) was increased in the presence of the transgene ( Figure 2).
  • the fluorescence from tryptophan (ex 280, em 333), an internal standard of protein concentration, did not significantly vary between the groups.
  • Methylamine supplementation promotes hypertension.
  • Systolic arterial blood pressure and heart rate were measured in all of the groups using the tail cuff method. Methylamine supplementation significantly elevated blood pressure but did not affect heart rate. A trend for elevated blood pressure was also found with the transgene alone.
  • Methylamine supplementation and the mTIEhVAP-1 transgene modify the progression of atherosclerosis.
  • the percentage of aorta surface area positive for Oil Red O staining was determined for the mice in each group.
  • Methylamine supplementation increased the percentage of lesion formation when compared to untreated controls.
  • the transgene decreased the number of lesions found in each aorta while leaving the total area of lesion formation unchanged suggesting that individual lesions are larger.
  • niTIEhVAP-1 transgene inhibits renal and glomerular hypertrophy while at the same time promoting glomerulosclerosis.
  • Glomeruloscerosis is the main renal lesion in human and experimental diabetes. Its pathogenesis is controversial and the role of renal and glomerular hypertrophy in the pathogenesis of glomeruloscerosis is unclear. In this study, the two renal pathologies were uncoupled.
  • kidney sections revealed glomerulosclerosis (decreased capillary space, increased cell number, increased extracellular matrix, and a thicker glomerular stalk) in transgenic mice fed the atherogenic diet. Mild glomerular lesions were also found in non-transgenic mice fed the atherogenic diet but to a lesser extent than in the transgenic mice. In addition, occasional glomerular cysts were present in the transgenic mice fed the atherogenic diet but were not present in the similarly fed non-transgenic mice.
  • hydrogen peroxide can produce insulin-like effects that may be important for both obesity (lipogenesis promotion and lipolysis inhibition) and metabolic syndrome (increased glucose uptake) and on the other hand hydrogen peroxide is a key reactive oxygen species (ROS) that is implicated in endothelial cell toxicity and cardiovascular pathology.
  • ROS reactive oxygen species
  • ammonia and formaldehyde are extremely reactive and cytotoxic chemicals that can promote aberrant, non-enzymatic glycation of proteins and may either directly or subsequently contribute to the late complications of diabetes such as hypertension, atherosclerosis and nephropathy.
  • VAP-I activity may be increased in metabolic syndrome as an attempt to regulate blood glucose levels and that vascular damage is subsequently promoted as a secondary consequence of this chronic enzyme activity. This suggests that manipulation of VAP-I has potential to serve as a therapeutic treatment in conditions related to metabolic syndrome.
  • AGE- specific fluorescence spectra (ex 360/em 465) of non-transgenic (NT, open bars) and transgenic (TG, solid bars) mice after chronic feeding with normal food (chow) and water (tap), methylamine supplemented water (Methyl.), or an atherogenic diet (athero.).
  • NT non-transgenic
  • TG transgenic mice after chronic feeding with normal food (chow) and water (tap), methylamine supplemented water (Methyl.), or an atherogenic diet (athero.).
  • AU arbitrary units.
  • SSAO activity is increased in diabetes as an attempt to regulate blood glucose levels and that vascular complications are subsequently promoted as a secondary consequence of chronic SSAO activity.
  • VAP-I When the in vivo levels of VAP-I are increased the potential for SSAO activity is increased.
  • the deamination of primary amines, such as methylamine, by VAP-I produces the biologically active compounds hydrogen peroxide, ammonia, and aldehyde. These compounds in turn can produce beneficial insulin-like effects while at the same time promoting AGE formation and vascular damage.
  • Vitamin Bl and its metabolites as VAP-I inhibitors (reference example):
  • SSAO activity of the cells was measured using Amplex Red reagent (10-acetyl-3,7- dihydroxyphenoxazine; Molecular Probes Europe BV), a highly sensitive and stable probe for H 2 O 2 .
  • Cultured cells (VAP-I transfected CHO cells and their mock transfected controls) were rinsed with Krebs Ringer phosphate glucose (KRPG; 145 mM NaCl, 5.7 mM sodium phosphate, 4.86 mM KCl, 0.54 mM CaCl 2 , 1.22 mM MgSO 4 , 5.5 mM glucose, pH 7.35) and pre-incubated 30 min at 37°C in 200 ⁇ l KRPG containing thiamine, penicillin or ampicillin (lmg/ml).
  • KRPG Krebs Ringer phosphate glucose
  • Catalytic reaction was initiated by addition of benzylamine as substrates and H 2 C ⁇ 2 -detecting mixture containing horseradish peroxidase (final concentration 0.8 U/ml) and Amplex Red reagent (60 ⁇ M). The plates were incubated for 1-2 hours at 37°C in the final volume of 250 ⁇ l, the bathing medium was clarified by centrifugation and placed in aliquots (200 ⁇ l) into white non-phosphorescent microplates (Cliniplate).
  • H 2 O 2 concentration was calculated from calibration curves generated by serial dilutions of either standard H 2 O 2 or resorufin, the product of the Amplex Red reaction (Molecular Probes).
  • Amine oxidase activity was assayed radiochemical ⁇ using [7- 14 C]-benzylamine hydrochloride (spec. act. 57 mCi/mmol, Amersham) as a substrate and 25 microliters of serum.
  • the reaction was initiated by addition of 6 ⁇ mol/L [ 14 C]- benzylamine (40000 dpm) and terminated after 1 hour by citric acid.
  • the aldehydes were extracted into toluene containing diphenyloxazole and the formation of [ 14 C]- labelled benzaldehyde was quantified by scintillation counting. Potential inhibition of serum VAP-I /S SAO enzymatic activity was measured in presence of indicated concentrations of thiamine.
  • the inhibitory percentages obtained with thiamine after treating VAP-I transfected CHO cells in fluorometric assays are listed in Table 1. Controls, pencillin and ampicillin, did not inhibit the activity.
  • In vitro thiamine decreased serum VAP- 1/SSAO activity as follows: 1 mg/ml , 87%; 800 micrograms/ml, 70%; 400 micrograms/ml 39%; 200 micrograms/ml 32%.
  • In vivo response of VAP-1/SSAO enzymatic activity to vitamin Bl varied between individuals. Four of the six volunteers responded to vitamin B. Their VAP-I enzyme activity at the end of the experiment had decreased: 25, 2, 32 and 16 % (mean 19%).
  • the benfothiamine dose was low and it was eaten only for four days, it decreased SSAO activity of each individual (9, 24, 8 and 27%).
  • vitamin Bl derivative 3-(2-aminobenzyl)-5-(2-hydroxyethyl)-4-methyl- thiazolium chloride hydrochloride (FP-1113) as inhibitor of SSAO activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de la vitamine B1, de dérivés de la vitamine B1 ou de précurseurs de la vitamine B1 en tant qu'inhibiteurs des amines oxydases sensibles au semicarbazide (SSAO), chez des individus non-diabétiques. L'invention porte en particulier sur leur utilisation dans le traitement ou la prévention du syndrome métabolique et de maladies ou d'états en résultant. En outre, la présente invention concerne des produits alimentaires ou des additifs alimentaires comprenant un inhibiteur d'enzyme amine oxydase qui est un dérivé de la vitamine B1 ou un précurseur de la vitamine B1. L'invention porte également sur de nouveaux dérivés de la vitamine B1 et sur leur utilisation.
PCT/FI2007/000206 2004-01-30 2007-08-22 Compositions utiles en particulier dans le traitement ou la prévention du syndrome métabolique WO2008025870A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07803696A EP2056830A4 (fr) 2006-08-28 2007-08-22 Compositions utiles en particulier dans le traitement ou la prévention du syndrome métabolique
US12/060,533 US8119651B2 (en) 2004-01-30 2008-04-01 Compositions useful especially for treatment or prevention of metabolic syndrome
US13/354,025 US20120115815A1 (en) 2004-01-30 2012-01-19 Compositions useful especially for treatment or prevention of metabolic syndrome

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20060768 2006-08-28
FI20060768A FI20060768A0 (fi) 2006-08-28 2006-08-28 Erityisesti metabolia-oireyhtymän hoitoon tai ehkäisyyn soveltuvia koostumuksia

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2005/000035 Continuation-In-Part WO2005072738A1 (fr) 2004-01-30 2005-01-19 Compositions particulierement utiles au traitement ou a la prevention du syndrome metabolique

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/488,914 Continuation-In-Part US20070191408A1 (en) 2004-01-30 2006-07-19 Compositions useful especially for treatment or prevention of metabolic syndrome

Publications (1)

Publication Number Publication Date
WO2008025870A1 true WO2008025870A1 (fr) 2008-03-06

Family

ID=36950669

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FI2007/000206 WO2008025870A1 (fr) 2004-01-30 2007-08-22 Compositions utiles en particulier dans le traitement ou la prévention du syndrome métabolique

Country Status (3)

Country Link
EP (1) EP2056830A4 (fr)
FI (1) FI20060768A0 (fr)
WO (1) WO2008025870A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023207A1 (fr) * 2007-08-13 2009-02-19 Synvista Therapeutics, Inc. Composés de thiazolium pour le traitement des complications gastro-intestinales
WO2009051804A1 (fr) * 2007-10-18 2009-04-23 Synvista Therapeutics, Inc. Composés de thiazolium destinés au traitement ou à la prévention de maladies associées à une résistance à l'insuline
WO2010026272A1 (fr) 2008-09-03 2010-03-11 Universitat Autònoma De Barcelona Méthodes et compositions pour le traitement et le diagnostic de la transformation hémorragique
WO2014199171A1 (fr) 2013-06-12 2014-12-18 Proximagen Limited Nouvelles utilisations thérapeutiques d'inhibiteurs enzymatiques
WO2015189534A1 (fr) 2014-06-12 2015-12-17 Proximagen Limited Inhibiteurs de vap-1 pour le traitement de la dystrophie musculaire
EP3777846A1 (fr) 2015-12-07 2021-02-17 BenevolentAI Cambridge Limited Inhibiteurs de vap-1 for traitmanet de la douleur
WO2021059275A1 (fr) * 2019-09-26 2021-04-01 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Thérapie à base de thiamine pour des maladies associées à la stéatose hépatique

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558050A (en) * 1984-03-01 1985-12-10 University Of Florida Treatment of metabolic disorders with dichloroacetate-thiamine preparations
EP0511587A1 (fr) * 1991-04-26 1992-11-04 Takeda Chemical Industries, Ltd. Composition amaigrissante
EP0820770A2 (fr) * 1996-07-24 1998-01-28 WÖRWAG PHARMA GmbH Composition pharmaceutique pour le traitement de neuropathies contenant une thiamine liposoluble et un antioxydant
EP0820771A2 (fr) * 1996-07-24 1998-01-28 WÖRWAG PHARMA GmbH Composition pharmaceutique pour le traitement de neuropathies contenant une thiamine liposoluble et un composé de magnésium
US5853703A (en) * 1995-01-18 1998-12-29 The Picower Institute For Medical Research Preventing and reversing the formation of advanced glycosylation endproducts
DE10353535A1 (de) * 2003-11-14 2005-06-16 Bayer Healthcare Ag Vitaminkombination, enthaltend Benfotiamin
WO2005072738A1 (fr) * 2004-01-30 2005-08-11 Faron Pharmaceuticals Oy Compositions particulierement utiles au traitement ou a la prevention du syndrome metabolique
WO2005095391A1 (fr) * 2004-03-24 2005-10-13 Array Biopharma Inc. Thiazoliums comme inhibiteurs de la transcetolase
JP2006008576A (ja) * 2004-06-25 2006-01-12 Kosei Tanaka ヘキサミン生合成経路活性化抑制剤
US20060089316A1 (en) * 2004-10-25 2006-04-27 Brown Truman R Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4558050A (en) * 1984-03-01 1985-12-10 University Of Florida Treatment of metabolic disorders with dichloroacetate-thiamine preparations
EP0511587A1 (fr) * 1991-04-26 1992-11-04 Takeda Chemical Industries, Ltd. Composition amaigrissante
US5853703A (en) * 1995-01-18 1998-12-29 The Picower Institute For Medical Research Preventing and reversing the formation of advanced glycosylation endproducts
EP0820770A2 (fr) * 1996-07-24 1998-01-28 WÖRWAG PHARMA GmbH Composition pharmaceutique pour le traitement de neuropathies contenant une thiamine liposoluble et un antioxydant
EP0820771A2 (fr) * 1996-07-24 1998-01-28 WÖRWAG PHARMA GmbH Composition pharmaceutique pour le traitement de neuropathies contenant une thiamine liposoluble et un composé de magnésium
DE10353535A1 (de) * 2003-11-14 2005-06-16 Bayer Healthcare Ag Vitaminkombination, enthaltend Benfotiamin
WO2005072738A1 (fr) * 2004-01-30 2005-08-11 Faron Pharmaceuticals Oy Compositions particulierement utiles au traitement ou a la prevention du syndrome metabolique
WO2005095391A1 (fr) * 2004-03-24 2005-10-13 Array Biopharma Inc. Thiazoliums comme inhibiteurs de la transcetolase
JP2006008576A (ja) * 2004-06-25 2006-01-12 Kosei Tanaka ヘキサミン生合成経路活性化抑制剤
US20060089316A1 (en) * 2004-10-25 2006-04-27 Brown Truman R Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of EP2056830A4 *
TAKAMIZAWA A. ET AL.: "Studies on Pyrimidine Derivatives and Related Compounds. LXXVII. Reaction of Thiamine Analogues with Diethyl Benzoylphosphonate", CHEM. PHARM. BULL., vol. 21, no. 4, 1973, pages 770 - 784, XP002934385 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023207A1 (fr) * 2007-08-13 2009-02-19 Synvista Therapeutics, Inc. Composés de thiazolium pour le traitement des complications gastro-intestinales
WO2009051804A1 (fr) * 2007-10-18 2009-04-23 Synvista Therapeutics, Inc. Composés de thiazolium destinés au traitement ou à la prévention de maladies associées à une résistance à l'insuline
WO2010026272A1 (fr) 2008-09-03 2010-03-11 Universitat Autònoma De Barcelona Méthodes et compositions pour le traitement et le diagnostic de la transformation hémorragique
WO2014199171A1 (fr) 2013-06-12 2014-12-18 Proximagen Limited Nouvelles utilisations thérapeutiques d'inhibiteurs enzymatiques
WO2015189534A1 (fr) 2014-06-12 2015-12-17 Proximagen Limited Inhibiteurs de vap-1 pour le traitement de la dystrophie musculaire
EP3777846A1 (fr) 2015-12-07 2021-02-17 BenevolentAI Cambridge Limited Inhibiteurs de vap-1 for traitmanet de la douleur
WO2021059275A1 (fr) * 2019-09-26 2021-04-01 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Thérapie à base de thiamine pour des maladies associées à la stéatose hépatique

Also Published As

Publication number Publication date
EP2056830A4 (fr) 2011-01-12
FI20060768A0 (fi) 2006-08-28
EP2056830A1 (fr) 2009-05-13

Similar Documents

Publication Publication Date Title
EP1708711B1 (fr) Compositions particulierement utiles au traitement ou a la prevention du syndrome metabolique
Kopple et al. Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study
Abraham et al. Management of fibromyalgia: rationale for the use of magnesium and malic acid
EP0086079B1 (fr) Composition pour la réduction du poids
EP2512236B1 (fr) Procédé amélioré permettant d'administrer du bêta-hydroxy-bêta-méthylbutyrate (hmb)
WO2008025870A1 (fr) Compositions utiles en particulier dans le traitement ou la prévention du syndrome métabolique
Prasad Discovery of zinc for human health and biomarkers of zinc deficiency
EP2288364B1 (fr) Procédés de traitement ou de prévention du diabète mellitus et autres déséquilibres métaboliques
US20050214385A1 (en) Chromium/biotin treatment of dyslipidemia and diet-induced post prandial hyperglycemia
US20050008723A1 (en) Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
KR100989834B1 (ko) 키토올리고당을 함유하는 피로 개선용 조성물
WAKAMIYA et al. Vitamin C activity of 2-O-α-D-glucopyranosyl-L-ascorbic acid in guinea pigs
EP1014808B1 (fr) Acides gras utilises en tant que supplement dietetique
US20070191408A1 (en) Compositions useful especially for treatment or prevention of metabolic syndrome
US8119651B2 (en) Compositions useful especially for treatment or prevention of metabolic syndrome
Ito et al. Effects of a dietary magnesium deficiency and excess vitamin D3 on swine coronary arteries.
EA002435B1 (ru) Способ снижения уровня липопротеина (а) в сыворотке или в плазме крови млекопитающих
JP4585186B2 (ja) 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤
EP2067478A1 (fr) Agent préventif ou thérapeutique de l'élévation du taux de glucose sanguin
US20070093433A1 (en) Aminoglycoside antibiotics for use as vap-1/ssao inhibitors
Chvapil et al. On the mechanisms of β-aminopropionitrile toxicity
Vasilakes et al. Annotated Semantic Predications from SemMedDB
US20220202789A1 (en) Administration of berberine metabolites
WO2001028365A1 (fr) Supplement nutritionnel
Akarte et al. Studies on tryptophan-niacin metabolism in streptozotocin diabetic rats

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07803696

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007803696

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU